NeuroMetrix (NASDAQ:NURO) Stock Passes Above 200-Day Moving Average – Here’s What Happened

NeuroMetrix, Inc. (NASDAQ:NURO) crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $4.14 and traded as high as $4.52. NeuroMetrix shares last traded at $4.50, with a volume of 1,206 shares traded.

Analysts Set New Price Targets

Separately, StockNews.com initiated coverage on shares of NeuroMetrix in a research note on Friday. They issued a “sell” rating on the stock.

NeuroMetrix Price Performance

The firm has a market cap of $9.24 million, a PE ratio of -0.98 and a beta of 2.15. The company has a 50-day simple moving average of $4.34 and a 200-day simple moving average of $4.14.

Institutional Trading of NeuroMetrix

A hedge fund recently bought a new stake in NeuroMetrix stock. Renaissance Technologies LLC purchased a new position in NeuroMetrix, Inc. (NASDAQ:NURO) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 11,560 shares of the medical device company’s stock, valued at approximately $46,000. Renaissance Technologies LLC owned 0.57% of NeuroMetrix at the end of the most recent reporting period. Hedge funds and other institutional investors own 19.40% of the company’s stock.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.